Research programme: cancer antibody therapies - Celera/Seattle Genetics

Drug Profile

Research programme: cancer antibody therapies - Celera/Seattle Genetics

Latest Information Update: 03 Aug 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celera Genomics Group; Seattle Genetics
  • Developer Celera Corporation; Seattle Genetics
  • Class Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 20 Jun 2005 This programme is still in active development
  • 29 Jul 2004 Celera Genomics and Seattle Genetics have entered into an agreement to co-develop targeted antibody therapies in USA for cancer
  • 29 Jul 2004 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top